Altasciences, a contract research organization, and Certara, a biosimulation software company, announced a strategic partnership on May 7, 2026, to integrate Certara's AI-driven modeling and simulation tools into Altasciences' early-phase clinical services. The collaboration aims to enhance drug development efficiency by using virtual patients and predictive models to optimize study designs before human trials.
According to the press release, the partnership will leverage Certara's Simcyp and Phoenix platforms to simulate drug behavior, reducing the need for extensive animal testing and accelerating timelines. Altasciences will apply these tools to its Phase I and bioanalytical services, offering clients a more data-driven approach to candidate selection.
Financial terms of the agreement were not disclosed. The companies stated that the initiative is expected to improve success rates in early clinical trials and lower development costs for pharmaceutical sponsors.
